You are here

China cancer patients turn to unapproved drugs on grey market


WHEN her father's lung cancer worsened, Yin Min, a 51-year-old financial broker from Shanghai, faced a choice: pay nearly US$3,000 a month for an approved drug or pay a fraction of the price for a generic drug not approved for use in China.

Ms Yin, like many families in...

Market voices on: